Goldman Sachs analyst Madhu Kumar ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

Iovanace Biotherapeutics (IOVA) Has Strong Cash Cushion Even as CEO Exit Adds to Uncertainties - MizuhoMay 19, 2021 12:42 PM Iovanace Biotherapeutics (IOVA) PT Lowered to $33 at Stifel on BLA PushMay 19, 2021 8:05 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at Chardan Capital Markets on BLA DelayMay 19, 2021 7:58 AM